Promoting Safer Sex in HIV+ Homosexual and Bisexual Men Who Use Methamphetamine

This study has been completed.

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00291512

Purpose

This project studies the effectiveness of a sexual risk reduction intervention among HIV+ Men who have Sex with Men (MSM) and who use methamphetamine.

Condition	Intervention	Phase
HIV Infections STDs Methamphetamine Abuse	Behavioral: Theory-based counseling program	Phase II

MedlinePlus related topics: AIDS Methamphetamine

Drug Information available for: Amphetamine Methamphetamine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Promoting Safer Sex in HIV+ MSM Methamphetamine Users

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV+
Men who have sex with men

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00291512

Locations

United States, California
HIV Neurobehavioral Research Center
San Diego, California, United States, 92103

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Thomas L. Patterson, Ph.D.

University of California, San Diego

More Information

Study ID Numbers:	DESPR DA012116
Study First Received:	February 10, 2006
Last Updated:	November 12, 2008
ClinicalTrials.gov Identifier:	NCT00291512
Health Authority:	United States: Federal Government

Keywords provided by National Institute on Drug Abuse (NIDA):

HIV
STDs
Methamphetamine abuse
MSM

Study placed in the following topic categories:

Virus Diseases
Methamphetamine
Sexually Transmitted Diseases, Viral
Dopamine
HIV Infections

Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Amphetamine
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
RNA Virus Infections
Neurotransmitter Agents
Slow Virus Diseases
Adrenergic Agents
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Sympathomimetics

Physiological Effects of Drugs
Central Nervous System Stimulants
Infection
Pharmacologic Actions
Autonomic Agents
Therapeutic Uses
Lentivirus Infections
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 16, 2009